Want to read Slashdot from your mobile device? Point it at m.slashdot.org and keep reading!


Forgot your password?
DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Also, Slashdot's Facebook page has a chat bot now. Message it for stories and more. Check out the new SourceForge HTML5 internet speed test! ×

Comment Description of research (app. by Dr. Gudkov) (Score 1) 385

From this bio at Roswell Park Cancer Institute in Buffalo:

[describing his own various research interests ...]

Role of p53 in Cancer

Our p53 studies are focused on the mechanism and role of this TSG in how normal tissues respond to genotoxic stresses associated with cancer treatment. Our previous studies have shown tissue specificity of p53-mediated apoptosis and its major role in determining the radiation sensitivity of mammals. We defined p53 as a determinant of cancer treatment side effects; the new therapeutic conceptâ"targeting p53 for therapeutic suppressionâ"was justified by isolating a small molecule p53 inhibitor that rescues mice from lethal doses of gamma irradiation.

Analysis of an animal model of chemotherapy-induced hair loss (alopecia) has indicated that p53 plays a major role in this common side effect, thus opening another area for clinical application of p53 inhibitors.

Mechanisms of tissue specificity of the p53 response are being addressed by cDNA microarray-based analysis of tissue-specific p53 responsive genes. This direction of studies is linked to identification of new tumor markers among the genes that are under the negative control of p53, a mechanism we have shown to be a possible underlying cause of elevated prostate-specific antigen expression.

The role of p53-dependent apoptosis and growth arrest and the interaction of p53 with other signaling pathways (TNF, Fas, heat shock, etc.) in determining its tumor suppressor function is being analyzed in several model systems. The impact of distinct p53 function (i.e., control of growth arrest or apoptosis) in its tumor suppressor activity is under investigation. We showed that control of radiosensitivity of tissues by p53 in vivo does not involve the p21/waf1 p53-responsive CDK inhibitor. Induction of apoptosis was found to be dispensable for p53-mediated control of genomic stability; moreover, suppression of p53-dependent apoptosis by Bcl-2 delays tumor progression by eliminating selective advantages for genetically unstable p53-deficient cells.

Having already defined ING1, Bloom syndrome and SUMO proteins as p53 interactors, we are continuing the search for cellular modulators of p53 expression and function among p53-interacting proteins; several additional candidates are under study.

Drug Discovery Program

Our drug discovery program involves searching for new p53 inhibitors and testing their potential therapeutic applications for reducing cancer treatment side effects and possibly other pathologies involving p53-inducing stresses. It is based on creation of new cell-based readout systems and high-throughput screening of chemicals with the desired biological properties.

We are also isolating a new class of small molecules acting as modulators of multi-drug transporters that can greatly change the pattern of cross-resistance, including the ability to enhance their activity against certain compounds. The molecular mechanisms of activity of newly isolated compounds are being addressed, as are therapeutic fields for their practical applications.

  • Elena Feinstein, M.D., Ph.D. (Quark Biotech, Inc., Nes Ziona, Israel)
  • Peter Chumakov, MD, Ph.D. (Lerner Research Institute, CCF)
  • Michelle Haber, Ph.D. & Murray Norris, Ph.D. (Children's Cancer Institute of Australia, Sydney)
  • Raymond Tubbs, MD (Pathology, CCF)
  • Mikhail Nikiforov, Ph.D. (University of Michigan)
  • Mark Whitnall, Ph.D. (Armed Forces Radiobiology Research Institute)
  • Boris Naroditsky, Ph.D. (Gamaleya Institute of Microbiology, Russia)
  • Bruce Blazar, MD (University of Minnesota)
  • Joseph DiDonato, Ph.D. (Lerner Research Institute, CCF)
  • George R. Stark, Ph.D. (Lerner Research Institute, CCF)
  • Eric Klein, MD (CCF)
  • Oskar W. Rokhlin, Ph.D. (University of Iowa)

Slashdot Top Deals

Prototype designs always work. -- Don Vonada